Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy

Human Langerhans cells use an IL-15R- /IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1

(2012) E. Romano et al.   BLOOD

The differential production of cytokines by human Langerhans cells and dermal CD14+ DCs controls CTL priming

(2012) J. Banchereau et al.   BLOOD

Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

(2011) E. Romano et al.   CLINICAL CANCER RESEARCH

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

(2010) V. F. Van Tendeloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial

(2009) Ann Van Driessche et al.   CYTOTHERAPY

Functional Specializations of Human Epidermal Langerhans Cells and CD14+ Dermal Dendritic Cells

(2008) Eynav Klechevsky et al.   IMMUNITY